Cryopyrin-Associated Periodic Syndromes
New cryopyrin-associated periodic syndromes research, summarized each month in plain language.
2026 so far: In February-September 2026, differences tied to genetics stood out for CAPS severity and remission patterns, alongside added context on AA amyloidosis and early lab work on ways to control NLRP3. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- IL-1 blockers and dosing. Routine-care reports highlighted remission with IL-1 blockade and dose changes.
- AA amyloidosis risk. Reports added broader context and specific cohorts on amyloidosis burden.
- Genetics and mosaicism. More evidence emphasized mosaic variants and uncertain variants in diagnosis.
- Flares and procedures. Reports highlighted milder-group flare triggers and perioperative temperature monitoring.
- New biology targets. Multiple lab studies proposed new levers on NLRP3 activation.
New
September 2026
- Kidney damage risk. AA amyloidosis was uncommon, but could severely affect kidneys.
- Early warning sign. AA amyloidosis sometimes appeared before the autoinflammatory diagnosis.
- Transplant and death. Kidney transplant and death were reported in the overall AA group.
August 2026
- Genetic causes found. Genetic testing explained some unclear inflammatory diagnoses in children.
- NLRP3 gene variant. One child had an NLRP3 variant linked to cryopyrin inflammation.
- Hives interpretation. A case report described hives alongside a rare muscle-heart condition, not CAPS.
July 2026
- Neutrophil DNA webs. Lab models linked these webs to higher IL-1beta release.
- PAD4 enzyme role. Blocking PAD4 reduced the web material and inflammation in models.
- Mosaic gene changes. Low-level mosaic variants showed up in many referral diagnoses.
- AA amyloidosis reports. In late-onset mosaic CAPS, AA amyloidosis was reported in follow-up.
May 2026
- Time of day and NLRP3 activity. In lab immune-cell experiments, NLRP3-driven inflammation changed depending on time-of-day conditions.
- CRY proteins and IL-1β. In the same lab work, increasing CRY1/CRY2 activity was linked to lower IL-1β release and less inflammatory cell death.
- NLRP3 blocker and timing. The NLRP3 inhibitor MCC950 showed different levels of blocking under different time-of-day conditions in cells.
- Single-child case report. One report described a 10-year-old with CAPS and early AA amyloidosis whose symptoms improved and kidney function stabilized after IL-1 blockade.
April 2026
- NLRP3 variant and severity. In routine care reports, the type of NLRP3 gene variant tended to match how severe CAPS symptoms were.
- Milder symptom pattern. In milder cases, attacks were more often reported after infections, and digestive symptoms were noted more often.
- IL-1 blocker dosing and remission. Some people were reported to reach remission on IL-1 blockers, sometimes after dose increases.
- Anesthesia temperature monitoring. One single-patient report highlighted close temperature monitoring during anesthesia in CAPS.
March 2026
- Natural brake on NLRP3. Lab work suggests cofilin-1 may help keep NLRP3 less active in resting cells.
- Stress can weaken the brake. Oxidative stress signals may reduce how well cofilin-1 can limit NLRP3 during activation.
- Some mutations bind less. In lab experiments, some CAPS-linked NLRP3 variants bound cofilin-1 less strongly than typical NLRP3.
- Mouse models closer to CAPS range. New mouse lines carrying the full-length human NLRP3 gene were reported to reflect a range of CAPS severity.
February 2026
- Brain inflammation. Only the brain-entering NLRP3 blocker lowered brain inflammation signs.
- Brain immune cells. The brain-entering drug reduced immune cell build-up in brain tissue.
- Body inflammation. Both NLRP3 blockers lowered inflammation outside the brain.
Get the monthly update by email
Subscribe here to receive an email when a new monthly cryopyrin-associated periodic syndromes update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).